| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 5 | 2023 | 148 | 1.070 |
Why?
|
| Testosterone | 8 | 2013 | 76 | 0.930 |
Why?
|
| Humans | 40 | 2023 | 2493 | 0.920 |
Why?
|
| Atherosclerosis | 3 | 2013 | 14 | 0.850 |
Why?
|
| Middle Aged | 23 | 2023 | 799 | 0.760 |
Why?
|
| Male | 27 | 2020 | 1649 | 0.700 |
Why?
|
| Female | 23 | 2020 | 1733 | 0.600 |
Why?
|
| Aging | 3 | 2013 | 101 | 0.590 |
Why?
|
| Prediabetic State | 2 | 2014 | 16 | 0.590 |
Why?
|
| Adult | 15 | 2022 | 807 | 0.590 |
Why?
|
| Aged | 15 | 2020 | 607 | 0.590 |
Why?
|
| Androgens | 2 | 2013 | 29 | 0.550 |
Why?
|
| United States | 15 | 2020 | 324 | 0.540 |
Why?
|
| Cholesterol | 2 | 2013 | 21 | 0.540 |
Why?
|
| Hyperlipidemias | 2 | 2013 | 6 | 0.480 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 4 | 0.470 |
Why?
|
| Insurance, Health | 1 | 2013 | 10 | 0.470 |
Why?
|
| Adolescent | 10 | 2018 | 305 | 0.400 |
Why?
|
| Primary Health Care | 4 | 2018 | 44 | 0.390 |
Why?
|
| Lipids | 3 | 2006 | 20 | 0.370 |
Why?
|
| African Americans | 1 | 2014 | 272 | 0.370 |
Why?
|
| United States Department of Veterans Affairs | 6 | 2020 | 9 | 0.360 |
Why?
|
| Quality of Health Care | 3 | 2016 | 10 | 0.360 |
Why?
|
| Veterans | 4 | 2019 | 6 | 0.360 |
Why?
|
| Cushing Syndrome | 3 | 2018 | 21 | 0.340 |
Why?
|
| Quality Improvement | 4 | 2019 | 10 | 0.330 |
Why?
|
| Parkinson Disease | 2 | 2019 | 3 | 0.320 |
Why?
|
| Young Adult | 5 | 2018 | 175 | 0.310 |
Why?
|
| Smoking Cessation | 2 | 2022 | 8 | 0.300 |
Why?
|
| Disease Management | 3 | 2019 | 10 | 0.290 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 5 | 0.280 |
Why?
|
| Glycated Hemoglobin A | 5 | 2019 | 64 | 0.250 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 2 | 0.240 |
Why?
|
| Depression | 2 | 2016 | 74 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2023 | 48 | 0.240 |
Why?
|
| Retrospective Studies | 7 | 2020 | 210 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 118 | 0.240 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 6 | 0.230 |
Why?
|
| Hypoglycemic Agents | 3 | 2023 | 83 | 0.220 |
Why?
|
| Muscle, Skeletal | 5 | 2006 | 87 | 0.220 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 3 | 0.210 |
Why?
|
| Mass Screening | 3 | 2014 | 66 | 0.200 |
Why?
|
| Heart Failure | 1 | 2020 | 4 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 246 | 0.200 |
Why?
|
| Telemedicine | 1 | 2020 | 31 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 5 | 0.180 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 16 | 0.180 |
Why?
|
| Metformin | 1 | 2019 | 13 | 0.180 |
Why?
|
| Health Promotion | 2 | 2019 | 31 | 0.180 |
Why?
|
| Internet | 1 | 2018 | 12 | 0.170 |
Why?
|
| Risk Factors | 3 | 2015 | 240 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2018 | 27 | 0.160 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2018 | 6 | 0.160 |
Why?
|
| Benzamides | 1 | 2018 | 13 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2018 | 53 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2018 | 102 | 0.150 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 2 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2016 | 23 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 267 | 0.150 |
Why?
|
| Birth Weight | 2 | 2013 | 22 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2016 | 17 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2016 | 19 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2015 | 7 | 0.140 |
Why?
|
| Hydrocortisone | 2 | 2018 | 27 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2015 | 5 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2015 | 3 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2015 | 20 | 0.140 |
Why?
|
| Receptors, Androgen | 2 | 2006 | 33 | 0.140 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 1 | 0.130 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 22 | 0.130 |
Why?
|
| Asthma | 1 | 2015 | 9 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2013 | 42 | 0.130 |
Why?
|
| Nicotine | 2 | 2018 | 89 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2015 | 13 | 0.130 |
Why?
|
| Insulin | 1 | 2015 | 109 | 0.130 |
Why?
|
| Triglycerides | 2 | 2021 | 36 | 0.130 |
Why?
|
| Waist Circumference | 1 | 2014 | 2 | 0.120 |
Why?
|
| Body Composition | 2 | 2011 | 35 | 0.120 |
Why?
|
| Community Health Services | 1 | 2014 | 22 | 0.120 |
Why?
|
| Quality of Life | 3 | 2023 | 60 | 0.120 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 1 | 0.120 |
Why?
|
| Medicaid | 1 | 2013 | 7 | 0.120 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 13 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2013 | 11 | 0.120 |
Why?
|
| Morphine Dependence | 1 | 2013 | 9 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2013 | 26 | 0.120 |
Why?
|
| Eating | 1 | 2013 | 18 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2019 | 121 | 0.120 |
Why?
|
| Hypertension | 1 | 2014 | 56 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 35 | 0.120 |
Why?
|
| Brain | 1 | 2013 | 55 | 0.120 |
Why?
|
| Morphine | 1 | 2013 | 44 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2013 | 46 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2012 | 5 | 0.110 |
Why?
|
| Infant Formula | 1 | 2012 | 1 | 0.110 |
Why?
|
| Infant, Extremely Premature | 1 | 2012 | 1 | 0.110 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 2 | 0.110 |
Why?
|
| Vitamin D | 1 | 2012 | 21 | 0.110 |
Why?
|
| Milk, Human | 1 | 2012 | 3 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 2012 | 6 | 0.110 |
Why?
|
| HIV Infections | 2 | 2004 | 91 | 0.110 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2012 | 2 | 0.110 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2012 | 12 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 31 | 0.110 |
Why?
|
| Needs Assessment | 2 | 2009 | 10 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 35 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2019 | 119 | 0.100 |
Why?
|
| Mice | 4 | 2018 | 508 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 95 | 0.100 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 12 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 23 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 185 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2006 | 35 | 0.090 |
Why?
|
| United States Indian Health Service | 1 | 2009 | 1 | 0.090 |
Why?
|
| Health Services | 1 | 2009 | 9 | 0.090 |
Why?
|
| Health Services Research | 1 | 2009 | 21 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 2 | 2006 | 10 | 0.090 |
Why?
|
| Animals | 4 | 2018 | 1238 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 61 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2020 | 56 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2008 | 29 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2008 | 4 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2008 | 2 | 0.080 |
Why?
|
| Caregivers | 1 | 2008 | 4 | 0.080 |
Why?
|
| Family Relations | 1 | 2008 | 6 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 14 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 14 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 30 | 0.080 |
Why?
|
| Dementia | 1 | 2007 | 4 | 0.080 |
Why?
|
| Pituitary Gland | 1 | 2007 | 35 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 1 | 0.080 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 1 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 4 | 0.080 |
Why?
|
| Muscle Contraction | 2 | 2004 | 11 | 0.080 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 5 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 9 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 13 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2006 | 9 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 3 | 0.070 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2006 | 7 | 0.070 |
Why?
|
| Body Weight | 3 | 2013 | 65 | 0.070 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 40 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 21 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 22 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2016 | 23 | 0.070 |
Why?
|
| Postmenopause | 1 | 2005 | 10 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2006 | 70 | 0.070 |
Why?
|
| Smoking | 2 | 2022 | 49 | 0.070 |
Why?
|
| HIV Wasting Syndrome | 1 | 2004 | 5 | 0.070 |
Why?
|
| Weight Loss | 1 | 2004 | 17 | 0.070 |
Why?
|
| Androstenedione | 1 | 2004 | 6 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 46 | 0.070 |
Why?
|
| Hypogonadism | 1 | 2004 | 13 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 24 | 0.060 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2018 | 3 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2015 | 64 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2015 | 110 | 0.060 |
Why?
|
| Leg | 1 | 2003 | 1 | 0.060 |
Why?
|
| Muscle Fatigue | 1 | 2003 | 1 | 0.060 |
Why?
|
| Child | 2 | 2015 | 126 | 0.060 |
Why?
|
| Prebiotics | 1 | 2023 | 1 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2002 | 4 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 8 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2013 | 49 | 0.060 |
Why?
|
| Time Factors | 2 | 2013 | 120 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 33 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 49 | 0.060 |
Why?
|
| Logistic Models | 2 | 2016 | 64 | 0.060 |
Why?
|
| Smokers | 1 | 2022 | 3 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 24 | 0.050 |
Why?
|
| Blood Viscosity | 1 | 2021 | 1 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2021 | 2 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 40 | 0.050 |
Why?
|
| Medical Records | 2 | 2015 | 18 | 0.050 |
Why?
|
| Antimalarials | 1 | 2019 | 3 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2019 | 11 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2019 | 28 | 0.050 |
Why?
|
| Nurses | 1 | 2019 | 3 | 0.040 |
Why?
|
| Health Information Exchange | 1 | 2018 | 1 | 0.040 |
Why?
|
| Health Personnel | 1 | 2018 | 13 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 10 | 0.040 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 23 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 31 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 54 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 116 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 3 | 0.040 |
Why?
|
| Comorbidity | 1 | 2016 | 54 | 0.040 |
Why?
|
| Research Design | 1 | 2016 | 17 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2018 | 180 | 0.040 |
Why?
|
| Sex Factors | 1 | 2016 | 75 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 45 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2016 | 2 | 0.040 |
Why?
|
| Decision Trees | 1 | 2016 | 3 | 0.040 |
Why?
|
| Weight Gain | 1 | 2015 | 10 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 9 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 18 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 90 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 97 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 210 | 0.030 |
Why?
|
| Drug Implants | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2013 | 5 | 0.030 |
Why?
|
| Texas | 1 | 2013 | 1 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 8 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 21 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 20 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 14 | 0.030 |
Why?
|
| Infant | 1 | 2013 | 52 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 68 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2012 | 1 | 0.030 |
Why?
|
| Veterans Health | 1 | 2012 | 1 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2012 | 4 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2012 | 21 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2012 | 13 | 0.030 |
Why?
|
| Motivation | 1 | 2012 | 24 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 36 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2012 | 1 | 0.030 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2012 | 1 | 0.030 |
Why?
|
| Austria | 1 | 2012 | 2 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 3 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 3 | 0.030 |
Why?
|
| Gestational Age | 1 | 2012 | 29 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 26 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2011 | 7 | 0.030 |
Why?
|
| Energy Intake | 1 | 2011 | 11 | 0.030 |
Why?
|
| Adiposity | 1 | 2011 | 18 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2011 | 18 | 0.030 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2010 | 2 | 0.020 |
Why?
|
| Saliva | 1 | 2010 | 3 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 114 | 0.020 |
Why?
|
| Home Nursing | 1 | 2008 | 1 | 0.020 |
Why?
|
| Community Networks | 1 | 2008 | 4 | 0.020 |
Why?
|
| Software | 1 | 2008 | 11 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 15 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2008 | 17 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 39 | 0.020 |
Why?
|
| California | 1 | 2008 | 93 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 64 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2007 | 10 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 4 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2006 | 1 | 0.020 |
Why?
|
| Enema | 1 | 2006 | 1 | 0.020 |
Why?
|
| Occult Blood | 1 | 2006 | 4 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 8 | 0.020 |
Why?
|
| Myogenin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 11 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2006 | 11 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 16 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 10 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2006 | 8 | 0.020 |
Why?
|
| Cell Division | 1 | 2006 | 39 | 0.020 |
Why?
|
| Drug Design | 1 | 2006 | 3 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2006 | 8 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 133 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2005 | 3 | 0.020 |
Why?
|
| Gels | 1 | 2005 | 5 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 7 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hematocrit | 1 | 2005 | 11 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2005 | 8 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 9 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 26 | 0.020 |
Why?
|
| Prostate | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2005 | 15 | 0.020 |
Why?
|
| Menstruation | 1 | 2004 | 3 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2004 | 21 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2004 | 16 | 0.020 |
Why?
|
| Kinetics | 1 | 2004 | 44 | 0.020 |
Why?
|
| Ligands | 1 | 2004 | 15 | 0.020 |
Why?
|
| Reference Values | 1 | 2004 | 42 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2004 | 79 | 0.020 |
Why?
|
| Registries | 1 | 2004 | 18 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2003 | 6 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 21 | 0.010 |
Why?
|
| Exercise | 1 | 2003 | 24 | 0.010 |
Why?
|